Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The peptide itself GHK consists of three amino acids: glycine (G), histidine (H), and lysine (K)
Practitioners are encouraged to stay updated with ongoing research and contribute to studies that explore these biochemical pathways
.png)
E., Elgueta, L., Segovia, E., and Cano, M
Upon ligand binding, GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, collectively improving glycemic control and promoting clinically meaningful weight reduction [19]
Semaglutide is a prescription-only medication in the United States
)
